Novartis is doubling down on the Triangle. The drug giant announced Thursday that it will build a 56,200-square-foot active pharmaceutical ingredient (API) manufacturing facility in Morrisville to supply ingredients for solid-dose tablets, capsules and RNA-based therapies. It is the latest move in a broader U.S. buildout as the company shifts more production stateside, and it slots neatly into a local life-sciences scene that shows no signs of cooling off.
What Novartis Is Building
In a company release, Novartis said the Morrisville facility will focus on producing active pharmaceutical ingredients for solid-dose tablets, capsules and RNA therapeutics. The site is one piece of a larger manufacturing puzzle: it is the seventh new U.S. facility the company has planned since rolling out a $23 billion investment in domestic manufacturing and research and development.
According to company materials, the Morrisville plant is intended to strengthen Novartis’ end-to-end U.S. production, covering everything from drug substance to finished medicine. In other words, more of the work that gets a pill from concept to pharmacy shelf will happen within U.S. borders.
Where It Fits In North Carolina
The new Morrisville project will bring Novartis’ footprint in North Carolina to five facilities across three locations, according to local reporting. As reported by ABC11, the company says the infrastructure in the Triangle will support both its current medicines and future therapies, including advanced RNA-based drugs.
"By building a connected, end-to-end footprint, we are strengthening our ability to locally develop, produce, and deliver medicines at scale," CEO Vas Narasimhan said in a statement, per ABC11. Novartis also pointed to recent U.S. investments this year in California, Texas and Florida as part of the same push to reinforce its domestic network.
State Support and Jobs
The Morrisville facility is woven into a broader North Carolina strategy that has already come with state incentives and job commitments. In November 2025 the North Carolina Department of Commerce announced that Novartis’ expansion across Durham and Wake counties was tied to roughly $771 million in investment and an expectation of about 700 new jobs, according to a state press release from that announcement. North Carolina Department of Commerce
Why The Triangle Keeps Drawing Drugmakers
Novartis is hardly alone in staking out manufacturing space in the Triangle. The Morrisville project lands as other big pharma names continue to roll out large-scale builds in the region, a trend industry coverage connects to local hiring pipelines and shipping advantages that are hard to beat.
Recent reporting highlights major investments by companies such as AbbVie and Genentech, underscoring the Triangle’s growing role as a national production hub. Industry outlets including FiercePharma and Construction Dive note that universities, community college training programs and established supplier networks all stack the deck in the region’s favor.
Work on Novartis’ broader North Carolina hub is already underway, following a December 2025 groundbreaking, and company officials say the Morrisville API site is meant to make its U.S. manufacturing network more resilient. Novartis has not given a firm opening date for the Morrisville facility, but says the project completes the seven-facility expansion plan the company has rolled out over the past year. Novartis
